Publications by authors named "Magda Bahcall"

Claim this Profile
E
Editor's Note: Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
Curtis R Chong, Magda Bahcall, Marzia Capelletti, Takayuki Kosaka, Dalia Ercan

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC.
Seshiru Nakazawa, Federica Pecci, Biagio Ricciuti, Felix H Gottlieb, Francesco Facchinetti, Magda Bahcall

J Thorac Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada, Jessica K Lee, Magda Bahcall

Cancer Discov· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.
Ciric To, Tyler S Beyett, Jaebong Jang, William W Feng, Magda Bahcall

Nat Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers.
Yoshihisa Kobayashi, Chhayheng Chhoeu, Jiaqi Li, Kristin S Price, Lesli A Kiedrowski, Magda Bahcall

Nature· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.
Magda Bahcall, Cloud P Paweletz, Yanan Kuang, Luke J Taus, Taebo Sim

Mol Cancer Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of -mutant lung cancer.
Pınar Özden Eser, Raymond M Paranal, Jieun Son, Elena Ivanova, Yanan Kuang, Magda Bahcall

Sci Transl Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ERK Inhibitor LY3214996-Based Treatment Strategies for -Driven Lung Cancer.
Jens Köhler, Yutong Zhao, Jiaqi Li, Prafulla C Gokhale, Hong L Tiv, Magda Bahcall

Mol Cancer Ther· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Gonzalo Recondo, Magda Bahcall, Liam F Spurr, Jianwei Che, Biagio Ricciuti

Clin Cancer Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for Mutant Non-Small Cell Lung Cancer.
Elena Ivanova, Mari Kuraguchi, Man Xu, Andrew J Portell, Luke Taus, Magda Bahcall

Clin Cancer Res· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.
Kari J Kurppa, Yao Liu, Ciric To, Tinghu Zhang, Mengyang Fan, Magda Bahcall

Cancer Cell· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amplification of Wild-type Imparts Resistance to Crizotinib in Exon 14 Mutant Non-Small Cell Lung Cancer.
Magda Bahcall, Mark M Awad, Lynette M Sholl, Frederick H Wilson, Man Xu

Clin Cancer Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK).
Chelsea E Powell, Yang Gao, Li Tan, Katherine A Donovan, Radosław P Nowak, Magda Bahcall

J Med Chem· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a potent dual ALK and EGFR T790M inhibitor.
Jaebong Jang, Jung Beom Son, Ciric To, Magda Bahcall, So Young Kim

Eur J Med Chem· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
Takayuki Kosaka, Junko Tanizaki, Raymond M Paranal, Hideki Endoh, Christine Lydon, Magda Bahcall

Cancer Res· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
Curtis R Chong, Magda Bahcall, Marzia Capelletti, Takayuki Kosaka, Dalia Ercan

Clin Cancer Res· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.
Magda Bahcall, Taebo Sim, Cloud P Paweletz, Jyoti D Patel, Ryan S Alden

Cancer Discov· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
John M Hatcher, Magda Bahcall, Hwan Geun Choi, Yang Gao, Taebo Sim

J Med Chem· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.
Junko Tanizaki, Dalia Ercan, Marzia Capelletti, Michael Dodge, Chunxiao Xu, Magda Bahcall

Cancer Res· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis